AUNA S.A.
No enriched coverage for $AUNA in the last 7 days.
No SEC Form 4 filings for $AUNA in the last 30 days.
See all $AUNA insider activity →Auna (AUNA) reported Q2 2026 results with 9% revenue growth driven by volume and higher complexity services. Adjusted EBITDA declined 9% due to margin pressures in Mexico and Colombia, and billing penalties in Peru. Mexico saw 7% surgery and 20% oncology volume growth, while Peru achieved 8% revenue growth. Colombia's adjusted EBITDA increased 18% sequentially. Leverage decreased to 3.6x, and cash increased 43% year-over-year.
Auna reported Q2 revenue growth in Mexico (4% YoY), Peru (8%), and Colombia (13%), but adjusted EBITDA varied. Mexico's EBITDA declined 16% YoY due to investments, while Peru's was flat due to billing penalties. Colombia's EBITDA fell 12% YoY but rose 18% sequentially. The company reaffirmed its full-year guidance, expecting 12% FX-neutral revenue growth and adjusted EBITDA growth toward the low end of its 10-14% target range, excluding Peru's billing penalties. Cash flow and leverage improved,
Auna S.A. reported Q2 2026 revenue growth of 9%, driven by high-complexity services, with adjusted EBITDA declining 9% due to investment costs. Management reaffirmed full-year revenue guidance of 12% growth and expects EBITDA growth at the low end of 10-14%. Free cash flow increased 181% due to working capital management. The company faces short-term penalties in Peru but anticipates improvements in profitability and cash flow.
Recent AUNA coverage spans earnings, insider activity and financial news.
Revenue growth may support upside, but EBITDA decline and margin pressure could weigh on price.
Earnings beat expectations on cash flow and leverage, but mixed EBITDA performance may pressure near-term price.
Earnings beat revenue expectations but margin pressure and guidance suggest modest upside.
2Q26 shows cash-flow strength and leverage improvement, but EBITDA margin pressure from service mix, costs, and Peru billing penalties. Guidance reaffirms revenue growth while EBITDA growth is expected only toward the low end.
Earnings beat on revenue but margin pressure; cash flow strong, leverage improved, expansion projects announced.
alphai scores every news story that mentions AUNA with an AI model for sentiment and relevance, and aggregates insider trades from AUNA S.A.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Auna (AUNA) reported Q2 2026 results with 9% revenue growth driven by volume and higher complexity services. Adjusted EBITDA declined 9% due to margin pressures in Mexico and Colombia, and billing penalties in Peru. Mexico saw 7% surgery and 20% oncology volume growth, while Peru achieved 8% revenue growth. Colombia's adjusted EBITDA increased 18% sequentially. Leverage decreased to 3.6x, and cash increased 43% year-over-year.
3 min readAuna reported Q2 revenue growth in Mexico (4% YoY), Peru (8%), and Colombia (13%), but adjusted EBITDA varied. Mexico's EBITDA declined 16% YoY due to investments, while Peru's was flat due to billing penalties. Colombia's EBITDA fell 12% YoY but rose 18% sequentially. The company reaffirmed its full-year guidance, expecting 12% FX-neutral revenue growth and adjusted EBITDA growth toward the low end of its 10-14% target range, excluding Peru's billing penalties. Cash flow and leverage improved,
3 min readAuna S.A. reported Q2 2026 revenue growth of 9%, driven by high-complexity services, with adjusted EBITDA declining 9% due to investment costs. Management reaffirmed full-year revenue guidance of 12% growth and expects EBITDA growth at the low end of 10-14%. Free cash flow increased 181% due to working capital management. The company faces short-term penalties in Peru but anticipates improvements in profitability and cash flow.
3 min readAuna S.A. (NYSE: AUNA) reported 2Q26 results with revenue up 9% FX-neutral to S/1,238 million, but Adjusted EBITDA down 9% FX-neutral to S/227 million. Operating cash flow and free cash flow rose 45% and 181% YoY, respectively. The company attributed EBITDA declines to service mix and cost pressures across its Latin American markets. Auna reaffirmed its full-year revenue guidance of 12% growth and expects Adjusted EBITDA growth at the low end of its 10-14% range.
6 min readAUNA S.A. (AUNA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Auna Announces 2Q26 Financial Results A consecutive quarter of strong top-line growth and cash flow performance; Consolidated Adjusted EBITDA impacted by service mix across the segments Luxembourg, August 18, 2026 – Auna (NYSE: AUNA) (“Auna” or the “Company”) , a lea
2 min readAuna S.A. (NYSE:AUNA) is covered by seven analysts. The average target implies ~32.6% upside, but JPMorgan on May 26 kept a Hold rating and cut its price target to $5 from $6. S&P Global shows a Buy consensus with an average target of $6.99. Fitch affirmed a B+ rating on May 22, citing material leverage; the outlook depends on execution across Latin American healthcare services.
4 min readZamora Leon Jesus (President) purchased 9,220 indirectly-held shares of AUNA S.A. (AUNA) at $4.17 on 2026-05-28.
1 min readZamora Leon Jesus (President) purchased 30,000 indirectly-held shares of AUNA S.A. (AUNA) at $4.39 ($0.13M total) on 2026-05-26.
1 min readZamora Leon Jesus (President) purchased 5,814 indirectly-held shares of AUNA S.A. (AUNA) at $4.39 on 2026-05-20.
2 min readZamora Leon Jesus (President) purchased 6,420 shares of AUNA S.A. (AUNA) at $4.15 on 2026-05-29.
2 min read
